Folgen
Mario Scartozzi
Mario Scartozzi
Bestätigte E-Mail-Adresse bei unica.it
Titel
Zitiert von
Zitiert von
Jahr
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
Journal of clinical oncology 27 (16), 2622-2629, 2009
4952009
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
M Scartozzi, E Galizia, S Chiorrini, R Giampieri, R Berardi, C Pierantoni, ...
Annals of oncology 20 (2), 227-230, 2009
3772009
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with …
M Scartozzi, I Bearzi, R Berardi, A Mandolesi, G Fabris, S Cascinu
Journal of clinical oncology 22 (23), 4772-4778, 2004
3242004
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D Santini, B Vincenzi, R Addeo, C Garufi, G Masi, M Scartozzi, A Mancuso, ...
Annals of Oncology 23 (9), 2313-2318, 2012
1802012
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
S Cascinu, R Berardi, R Labianca, S Siena, A Falcone, E Aitini, S Barni, ...
The lancet oncology 9 (1), 39-44, 2008
1662008
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy
M Scartozzi, I Bearzi, C Pierantoni, A Mandolesi, F Loupakis, A Zaniboni, ...
Journal of Clinical Oncology 25 (25), 3930-3935, 2007
1502007
Ten years of sorafenib in hepatocellular carcinoma: are there any predictive and/or prognostic markers?
G Marisi, A Cucchetti, P Ulivi, M Canale, G Cabibbo, L Solaini, FG Foschi, ...
World journal of gastroenterology 24 (36), 4152, 2018
1292018
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study
M Scartozzi, L Faloppi, G Svegliati Baroni, C Loretelli, F Piscaglia, ...
International journal of cancer 135 (5), 1247-1256, 2014
1282014
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
M Scartozzi, R Giampieri, E Maccaroni, M Del Prete, L Faloppi, ...
British journal of cancer 106 (5), 799-804, 2012
1162012
Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches
M Scartozzi, E Galizia, F Freddari, R Berardi, R Cellerino, S Cascinu
Cancer treatment reviews 30 (5), 451-459, 2004
1122004
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable …
S Cascinu, M Scartozzi, R Labianca, V Catalano, RR Silva, S Barni, ...
British journal of cancer 90 (8), 1521-1525, 2004
962004
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
AC Gardini, E Scarpi, L Faloppi, M Scartozzi, N Silvestris, D Santini, ...
Oncotarget 7 (41), 67142, 2016
942016
Immunotherapy for colorectal cancer: where are we heading?
D Basile, SK Garattini, M Bonotto, E Ongaro, M Casagrande, M Cattaneo, ...
Expert opinion on biological therapy 17 (6), 709-721, 2017
922017
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in …
M Scartozzi, I Bearzi, A Mandolesi, C Pierantoni, F Loupakis, A Zaniboni, ...
BMC cancer 9 (1), 1-8, 2009
912009
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
L Faloppi, M Scartozzi, M Bianconi, G Svegliati Baroni, P Toniutto, ...
BMC cancer 14 (1), 1-8, 2014
892014
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
M Scartozzi, M Bianconi, L Faloppi, C Loretelli, A Bittoni, M Del Prete, ...
British journal of cancer 108 (5), 1126-1132, 2013
882013
Mutations of hMLH1 and hMSH2 in Patients With Suspected Hereditary Nonpolyposis Colorectal Cancer: Correlation With Microsatellite Instability and …
M Scartozzi, F Bianchi, S Rosati, E Galizia, A Antolini, C Loretelli, A Piga, ...
Journal of clinical oncology 20 (5), 1203-1208, 2002
882002
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with …
F Graziano, F Arduini, A Ruzzo, A Mandolesi, I Bearzi, R Silva, P Muretto, ...
Annals of oncology 15 (3), 489-492, 2004
862004
HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research
F Pietrantonio, M Caporale, F Morano, M Scartozzi, A Gloghini, F De Vita, ...
International Journal of Cancer 139 (12), 2859-2864, 2016
842016
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy
C Madeddu, M Deidda, A Piras, C Cadeddu, L Demurtas, M Puzzoni, ...
Journal of cardiovascular medicine 17 (1), S12-S18, 2016
842016
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20